Urodilatin: A better natriuretic peptide?

Current Heart Failure Reports

Volumn 4, Issue 3, 2007, Pages 147-152

  Vesely, David L ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR ALPHA; BRAIN NATRIURETIC PEPTIDE; KALIURETIC PEPTIDE; LONG ACTING NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; PLACEBO; UNCLASSIFIED DRUG; URODILATIN; VESSEL DILATOR;

BRADYCARDIA; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DIURESIS; DIZZINESS; DRUG EFFECT; DRUG HALF LIFE; DRUG MEGADOSE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG CAPILLARY PRESSURE; META ANALYSIS; NATRIURESIS; NONHUMAN; PROTEIN LOCALIZATION; REVIEW; SIDE EFFECT; SWEATING; SYSTEMATIC REVIEW; TACHYCARDIA; UNSPECIFIED SIDE EFFECT;

ATRIAL NATRIURETIC FACTOR; BLOOD PRESSURE; CARDIAC OUTPUT; DIURESIS; DIURETICS; HEART FAILURE; HUMANS; PEPTIDE FRAGMENTS; PROGNOSIS; VASODILATION;

EID: 34848831146     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-007-0033-2     Document Type: Review

References (46)

1. Schulz-Knappe P, Forssmann K, Herbst F, et al.: Isolation and structural analysis of urodilatin, a new peptide of the cardiodilatin-(ANP)- family, extracted from human urine. Klin Wochenuschr 1988, 66:752-759.
2. Vesely DL: Atrial natriuretic peptide prohormone gene expression: hormones and diseases that upregulate its expression. IUBMB Life 2002, 53:153-159.
3. Vesely DL: Natriuretic hormones. In The Kidney: Physiology and Pathophysiology, edn 4. Edited by Alpern RJ, Hebert SC. San Diego: Elsevier/Academic Press; 2007:947-977.
4. Vesely BA, Eichelbaum EJ, Alli AA, et al.: Urodilatin and four cardiac hormones decrease human renal carcinoma cell number. Eur J Clin Invest 2006, 36:810-819.
5. Vesely DL, Norris JS, Walters JM, et al.: Atrial natriuretic prohormone peptides 1-30, 31-67, and 79-98 vasodilate the aorta. Biochem Biophys Res Commun 1987, 148:1540-1548.
6. Martin DR, Pevahouse JB, Trigg DJ, et al.: Three peptides from the ANF prohormone NH2-terminus are natriuretic and/or kaliuretic. Am J Physiol 1990, 258:F1401-F1408.
7. Gunning ME, Brady HR, Otuechere G, et al.: Atrial natriuretic peptide (31-67) inhibits Na transport in rabbit inner medullary collecting duct cells: role of prostaglandin E2. J Clin Invest 1992, 89:1411-1417.
8. Benjamin BA, Peterson TV: Effects of proANF (31-67) on sodium excretion in conscious monkeys. Am J Physiol 1995, 269:R1351-R1355.
9. Zeidel ML: Regulation of collecting duct Na+ reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995, 22:121-124.
10. Villarreal D, Reams GP, Taraben A, Freeman RH: Hemodynamic and renal effects of proANF 31-67 in hypertensive rats. Proc Soc Exp Biol Med 1990, 221:166-170.
11. Dietz JR, Scott DY, Landon CS, Nazian SJ: Evidence supporting a physiological role for proANP (1-30) in the regulation of renal excretion. Am J Physiol 2001, 280:R1510-R1517.
12. Vesely DL, Douglass MA, Dietz Jr, et al.: Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis and/or kaliuresis in humans. Circulation 1994, 90:1129-1140.
13. Vesely DL, Douglass MA, Dietz JR, et al.: Negative feedback of atrial natriuretic peptides. J Clin Endocrinol Metab 1994, 78:1128-1134.
14. Vesely DL, Dietz JR, Parks JR, et al.: Vessel dilator enhances sodium and water excretion and has beneficial hemodynamic effects in persons with congestive heart failure. Circulation 1998, 98:323-329.
15. Vesely DL, Dietz JR, Parks JR, et al.: Comparison of vessel dilator and long acting natriuretic peptide in the treatment of congestive heart failure. Am Heart J 1999, 138:652-632.
16. Nasser A, Dietz JR, Siddique M, et al.: Effects of kaliuretic peptide on sodium and water excretion in persons with congestive heart failure. Am J Cardiol 2001, 88:23-29.
17. Barr CS, Rhodes P, Struthers AD: C-Type natriuretic peptide. Peptides 1996, 17:1243-1251.
18. Lainchbury J, Richards AM, Nicholls MG: Brain natriuretic peptide in heart failure. In Atrial Natriuretic Peptides. Edited by Vesely DL. Trivandrum, India: Research Signpost; 1997:151-158.
19. Winters CJ, Sallman AL, Baker BJ, et al.: The N-terminus and a 4000 molecular weight peptide from the mid portion of the N-terminus of the atrial natriuretic factor prohormone each circulate in human and increase in congestive heart failure. Circulation 1989, 80:438-449.
20. Vesely DL, Norsk P, Winters CJ, et al.: Increased release of the N-terminal and C-terminal portions of the prohormone of atrial natriuretic factor during immersion-induced central hypervolemia in normal humans. Proc Soc Exp Biol Med 1989, 192:230-235.
21. Hunter EFM, Kelly PA Prowse C, et al.: Analysis of peptides derived from pro atrial natriuretic peptide that circulate in man and increase in heart disease. Scand J Clin Lab Invest 1998, 58:205-216.
22. Franz M, Woloszczuk W, Horl WH: N-terminal fragments of the proatrial natriuretic peptide in patients before and after hemodialysis treatment. Kidney Int 2000, 58:374-378.
23. De Palo EF, Woloszczuk W, Meneghetti M, et al.: Circulating immunoreactive proANP (1-30) and proANP (31-67) in sedentary subjects and athletes. Clin Chem 2000, 46:843-847.
24. Franz M, Woloszczuk W, Horl WH: Plasma concentration and urinary excretion of N-terminal proatrial natriuretic peptides in patients with kidney diseases. Kidney Int 2001, 59:1928-1934.
25. Vesely DL, Overton RM, Blankenship M, et al.: Atrial natriuretic peptide increases urodilatin in the circulation. Am J Nephrol 1998, 18:204-213.
26. Suga SI, Nakao K, Hosoda K, et al.: Receptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptide. Endocrinology 1992, 130:229-239.
27. Heim JM, Kiefersauer S, Fulle HJ, Gerzer R: Urodilatin and beta-ANP: Binding properties and activation of particulate guanylate cyclase. Biochem Biophys Res Commun 1989, 163:37-41.
28. Saxenhofer H, Fitzgibbon WR, Paul RV: Urodilatin: Binding properties and stimulation of cGMP generation in rat kidney cells. Am J Physiol 1993, 264:F267-F273.
29. Valentin JP, Sechi LA, Qiu C, et al.: Urodilatin binds to and activates renal receptors for atrial natriuretic peptide. Hypertension 1993, 21:432-438.
30. Ritter D, Chao J, Needleman P, et al.: Localization, synthetic regulation, and biology of renal atriopeptin-like prohormone. Am J Physiol 1992, 263:F503-F509.
31. Ramirez G, Saba SR, Dietz JR, Vesely DL: Immunocytochemical localization of proANF 1-30, proANF 31-67, and atrial natriuretic factor in the kidney. Kidney Int 1992, 41:334-341.
32. Greenwald JE, Needelman P, Wilkins MR, Schreiner GF: Renal synthesis of atriopeptin-like protein in physiology and pathophysiology. Am J Physiol 1991, 260:F602-F607.
33. Poulos JE, Gower WR Jr, Sullebarger JT, et al.: Congestive heart failure: Increased cardiac and extracardiac atrial natriuretic peptide gene expression. Cardiovasc Res 1996, 32:909-919.
34. Shin SJ, Lee YJ, Tan MS, et al.: Increased atrial natriuretic peptide mRNA expression in the kidney of diabetic rats. Kidney Int 1997, 51:1100-1105.
35. Totsune K, Mackenzie HS, Totsune H, et al.: Upregulation of atrial natriuretic peptide gene expression in remnant kidney of rats with reduced renal mass. J Am Soc Nephrol 1998, 9:1613-1617.
36. Mitrovic V, Lüss H, Nitsche K, et al.: Effects of the renal natriuretic peptide urodilatin (ularitide) in patients with decompensated chronic heart failure: a double-blind, placebo-controlled, ascending-dose trial. Am Heart J 2005, 150:1239. In this study of six patients in each of three treatment groups with 7.5, 15, and 30 ng/kg body weight/min of ularitide for 24 hours, PCWP decreased by 10 and 15 mmHg in the 15 and 30 ng ularitide groups and symptoms reported by patients tended to improve. There was no diuresis in any of the patients treated with these three doses of ularitide. Three of the 18 treated patients (17%) and 33% of the 30 ng/kg/min ularitide-treated patients developed hypotension with systolic blood pressure decreasing below 90 mmHg.
37. Kentsch M, Drummer C, Gerzer R, et al.: Severe hypotension and bradycardia after continuous intravenous infusion of urodilatin (ANP 95-126) in a patient with congestive heart failure. Eur J Clin Invest 1995, 25:281-283.
38. Mitrovic V, Seferovic PM, Simeunovic D, et al.: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006, 27:2823-2832. A larger follow-up study, with same findings as Mitrovic et al. [36••], where the same doses of ularitide decreased PCWP but did not cause a diuresis in persons with CHF.
39. Carstens J, Jensen KT, Pedersen EB: Metabolism and action of urodilatin infusion in healthy volunteers. Clin Pharmacol Ther 1998, 64:73-86.
40. Vesely DL: Which of the cardiac natriuretic peptides is the most effective for the treatment of congestive heart failure, renal failure, and cancer? Clin Exp Pharmacol Physiol 2006, 33:169-176.
41. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation 2005, 111:1487-1491. Meta-analysis of FDA and SCIOS data on nesiritide which revealed that nesiritide decreased PCWP and improved subjective symptoms but caused a high incidence (27%) of hypotension at its 0.06 mg/kg body weight/min concentration. In an evaluation of 1269 CHF patients, there was a 22% incidence of worsening of renal function as defined by an increase in creatinine of 0.5 mg or greater. Even in 906 patients with a low dose of 0.15 μg/kg/min or less, there was a 22% incidence of worsening of renal function.
42. Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Short-term risk of death after treatment with nesiritide for decompensated heart failure. A pooled analysis of randomized controlled trials. JAMA 2005, 293:1900-1905. Follow-up pool analysis of randomized, controlled trials suggested there was more than twofold increased risk of death in CHF patients at 30 days after receiving nesiritide.
43. Scriven TA, Burnett JC Jr: Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. Circulation 1985, 72:892-897.
44. Cody RJ, Atlas SA, Laragh JH, et al.: Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal and hemodynamic responses to peptide infusion. J Clin Invest 1986, 78:1362-1374.
45. Chiou S, Vesely DL: Kaliuretic peptide: the most potent inhibitor of Na+-K+-ATPase of the atrial natriuretic peptides. Endocrinology 1995, 136:2033-2039.
46. Vesely DL: Natriuretic peptides and acute renal failure. Am J Physiol 2003, 285:F167-F177.